万泰生物：预计2025年全年净亏损33,000万元—41,000万元

Core Viewpoint - WanTai Bio announced a significant expected net loss for 2025, projecting a net profit attributable to the parent company of between -330 million yuan and -410 million yuan, primarily due to challenges in both the vaccine and diagnostic segments [1] Vaccine Segment - The vaccine sector is under pressure from multiple factors including domestic vaccine procurement policies, industry competition, and consumer hesitancy, leading to a substantial decline in revenue and profit [1] - The company's bivalent HPV vaccine is adversely affected by the market presence of Merck's nine-valent HPV vaccine, significant price reductions in government procurement, and insufficient consumer demand, resulting in unsold near-expiry products and unconvertible inventory [1] - The company is actively addressing market and production challenges by managing product quality and has made provisions for impairment, which is expected to impact net profit by approximately 500 to 600 million yuan, contributing to the overall profit decline [1] Diagnostic Segment - The diagnostic segment is experiencing a decline in revenue and profit year-on-year due to national price reductions in diagnostic reagent procurement and changes in medical insurance policies [1] - The company is increasing investment in independent research and development, accelerating major projects such as installation and production lines, which has led to double-digit growth in specialty testing services for infectious diseases and thyroid function [1]